• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recent advances in neuroblastoma.

作者信息

Maris John M

机构信息

Center for Childhood Cancer Research, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, and Abramson Family Cancer Research Institute, Philadelphia, PA 19104-4318, USA.

出版信息

N Engl J Med. 2010 Jun 10;362(23):2202-11. doi: 10.1056/NEJMra0804577.

DOI:10.1056/NEJMra0804577
PMID:20558371
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3306838/
Abstract
摘要

相似文献

1
Recent advances in neuroblastoma.神经母细胞瘤的最新进展
N Engl J Med. 2010 Jun 10;362(23):2202-11. doi: 10.1056/NEJMra0804577.
2
Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials.复发、高危神经母细胞瘤患者的治疗和结局：德国试验的结果。
Pediatr Blood Cancer. 2011 Apr;56(4):578-83. doi: 10.1002/pbc.22693. Epub 2010 Dec 9.
3
[Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma].异环磷酰胺与卡铂化疗方案对复发性或难治性神经母细胞瘤的疗效
Ai Zheng. 2006 Dec;25(12):1550-2.
4
Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.强化化疗可提高伴有MYCN扩增的4期神经母细胞瘤患者的生存率。
J Pediatr Hematol Oncol. 2002 Nov;24(8):613-21. doi: 10.1097/00043426-200211000-00004.
5
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.大剂量化疗及自体造血干细胞救援用于高危神经母细胞瘤患儿
Cochrane Database Syst Rev. 2015 Oct 5;2015(10):CD006301. doi: 10.1002/14651858.CD006301.pub4.
6
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.大剂量化疗及自体造血干细胞救援用于高危神经母细胞瘤患儿
Cochrane Database Syst Rev. 2013 Aug 22(8):CD006301. doi: 10.1002/14651858.CD006301.pub3.
7
High-dose consolidation chemotherapy in infants with stage 4 neuroblastoma. The European Group for Bone Marrow Transplantation.4期神经母细胞瘤婴儿的大剂量巩固化疗。欧洲骨髓移植组。
Eur J Cancer. 1993;29A(11):1632. doi: 10.1016/0959-8049(93)90310-c.
8
The role of BMT for neuroblastoma relapse patients. A report of the EBMT-STR.骨髓移植对神经母细胞瘤复发患者的作用。欧洲血液与骨髓移植协作组-神经母细胞瘤登记处的报告。
Bone Marrow Transplant. 1991;7 Suppl 2:90.
9
Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.无 MYCN 扩增的非转移性和不可切除神经母细胞瘤婴儿减少治疗后取得良好效果：前瞻性 INES 99.1 研究结果。
J Clin Oncol. 2011 Feb 1;29(4):449-55. doi: 10.1200/JCO.2010.29.5196. Epub 2010 Dec 20.
10
Hodgkin's disease: treatment of relapsed disease.霍奇金淋巴瘤：复发疾病的治疗
Ann Oncol. 2002;13 Suppl 4:159-62. doi: 10.1093/annonc/mdf654.

引用本文的文献

1
Cantharidin Suppresses Cell Viability and Induces Apoptosis of SK-N-SH and SH-SY5Y Cells.斑蝥素抑制SK-N-SH和SH-SY5Y细胞的细胞活力并诱导其凋亡。
In Vivo. 2025 Sep-Oct;39(5):2634-2645. doi: 10.21873/invivo.14064.
2
25-Hydroxycholesterol Induces Intrinsic Apoptosis via Mitochondrial Pathway in BE(2)-C Human Neuroblastoma Cells.25-羟基胆固醇通过线粒体途径诱导BE(2)-C人神经母细胞瘤细胞发生内源性凋亡。
Int J Mol Sci. 2025 Aug 19;26(16):8012. doi: 10.3390/ijms26168012.
3
Mycn Is Essential for Pubertal Mammary Gland Development and Promotes the Activation of Bcl11b-Maintained Quiescent Stem Cells.

本文引用的文献

1
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.Hu14.18-IL2 治疗复发/难治性神经母细胞瘤的抗肿瘤活性：一项儿童肿瘤协作组（COG）的 II 期研究。
J Clin Oncol. 2010 Nov 20;28(33):4969-75. doi: 10.1200/JCO.2009.27.8861. Epub 2010 Oct 4.
2
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.拓扑替康联合环磷酰胺与拓扑替康单药治疗复发或难治性神经母细胞瘤患儿的 II 期随机对照研究：一项儿童肿瘤学组研究。
J Clin Oncol. 2010 Aug 20;28(24):3808-15. doi: 10.1200/JCO.2009.27.5016. Epub 2010 Jul 26.
3
Mycn对青春期乳腺发育至关重要，并促进由Bcl11b维持的静止干细胞的激活。
Cells. 2025 Aug 12;14(16):1239. doi: 10.3390/cells14161239.
4
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.针对高危神经母细胞瘤的GD2靶向嵌合抗原受体T细胞：一项1/2期试验。
Nat Med. 2025 Aug 21. doi: 10.1038/s41591-025-03874-6.
5
Design, synthesis, and biological evaluation of 5-chlorine-2-amino-pyrimidine derivatives as potent PLK4 inhibitors.5-氯-2-氨基嘧啶衍生物作为有效的PLK4抑制剂的设计、合成及生物学评价
RSC Med Chem. 2025 Aug 14. doi: 10.1039/d5md00435g.
6
The baseline F-FDG PET/CT imaging features in pediatric patients with congenital neuroblastoma.先天性神经母细胞瘤患儿的基线F-FDG PET/CT影像特征。
BMC Med Imaging. 2025 Aug 14;25(1):330. doi: 10.1186/s12880-025-01863-2.
7
AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression.AXL酪氨酸激酶抑制剂TP-0903通过靶向miR-335-3p/DKK1表达诱导活性氧触发神经母细胞瘤细胞凋亡。
Cell Death Discov. 2025 Aug 13;11(1):378. doi: 10.1038/s41420-025-02681-9.
8
Degradation of IRF6 by TRIM59 in tumor cells triggers PGM1-mediated glycolysis to regulate cell proliferation in neuroblastoma.TRIM59在肿瘤细胞中对IRF6的降解触发了PGM1介导的糖酵解，以调节神经母细胞瘤中的细胞增殖。
Cell Death Dis. 2025 Aug 12;16(1):613. doi: 10.1038/s41419-025-07932-2.
9
Integrative analysis of CRISPR screening and gene expression data identifies a three-gene prognostic model associated with immune microenvironment in neuroblastoma.CRISPR筛选与基因表达数据的综合分析确定了一种与神经母细胞瘤免疫微环境相关的三基因预后模型。
Transl Cancer Res. 2025 Jul 30;14(7):4058-4070. doi: 10.21037/tcr-2024-2472. Epub 2025 Jul 14.
10
Integrative single-cell and bulk transcriptomic analyses identify a robust four-gene signature for risk stratification in neuroblastoma.整合单细胞和批量转录组分析确定了一种用于神经母细胞瘤风险分层的强大四基因特征。
Transl Cancer Res. 2025 Jul 30;14(7):3920-3929. doi: 10.21037/tcr-2025-569. Epub 2025 Jul 4.
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
儿科临床前试验计划（PPTP）对极光激酶 A 抑制剂 MLN8237 的初步测试。
Pediatr Blood Cancer. 2010 Jul 15;55(1):26-34. doi: 10.1002/pbc.22430.
4
Inhibition of ALK signaling for cancer therapy.ALK 信号抑制在癌症治疗中的应用。
Clin Cancer Res. 2009 Sep 15;15(18):5609-14. doi: 10.1158/1078-0432.CCR-08-2762. Epub 2009 Sep 8.
5
Copy number variation at 1q21.1 associated with neuroblastoma.1q21.1处的拷贝数变异与神经母细胞瘤相关。
Nature. 2009 Jun 18;459(7249):987-91. doi: 10.1038/nature08035.
6
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.常见的 BARD1 变异影响高危神经母细胞瘤的易感性。
Nat Genet. 2009 Jun;41(6):718-23. doi: 10.1038/ng.374. Epub 2009 May 3.
7
Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.通过免疫细胞学和定量逆转录聚合酶链反应（QRT-PCR）灵敏检测骨髓、血液和干细胞制剂中微小神经母细胞瘤细胞的共识标准：国际神经母细胞瘤风险组工作组的建议
Br J Cancer. 2009 May 19;100(10):1627-37. doi: 10.1038/sj.bjc.6605029. Epub 2009 Apr 28.
8
Overall genomic pattern is a predictor of outcome in neuroblastoma.整体基因组模式是神经母细胞瘤预后的一个预测指标。
J Clin Oncol. 2009 Mar 1;27(7):1026-33. doi: 10.1200/JCO.2008.16.0630. Epub 2009 Jan 26.
9
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.国际神经母细胞瘤风险组（INRG）分类系统：INRG 工作组报告。
J Clin Oncol. 2009 Jan 10;27(2):289-97. doi: 10.1200/JCO.2008.16.6785. Epub 2008 Dec 1.
10
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.国际神经母细胞瘤风险组（INRG）分期系统：一份INRG特别工作组报告。
J Clin Oncol. 2009 Jan 10;27(2):298-303. doi: 10.1200/JCO.2008.16.6876. Epub 2008 Dec 1.